About Thymosin Alpha-1 Research

What this site is

Thymosin Alpha-1 Research is a graded reading of the peer-reviewed research literature on Thymosin Alpha-1 (thymalfasin), the 28-amino-acid thymic immunomodulatory peptide — each study summarized and sorted by how strong its evidence is. No clinic or pharmacy stands behind it; no one here sees patients, prescribes, or supplies the compound, and there is nothing to buy. The pages report what the studies measured and cite every figure — they do not diagnose, treat, or advise.

The "research" in our name describes the position we occupy relative to the literature — a reading desk that summarizes and grades published studies — not a claim that we conduct trials, offer treatment, or supply the compound. There is no clinic, pharmacy, or storefront behind this site.

How we read the evidence

We treat the Thymosin Alpha-1 record as a titration of evidence strength: some settings carry strong, reproducible human data (chronic viral hepatitis), some are null in the best trials (sepsis), some are mixed (COVID-19), and some are exploratory (HIV immune reconstitution). We report findings as study-attributed — tied to the population, dose, and route actually used — and we never assert unproven human benefit as established fact. Where a setting carries conflicting evidence, we cite the conflicting studies together.

We are careful about identity. Thymosin Alpha-1 is constantly confused with other thymic peptides, and we keep it distinct throughout from thymosin beta-4 / TB-500, thymulin, thymopentin, thymalin, and its own precursor prothymosin alpha. We also state regulatory reality plainly: it is not FDA-approved for marketing in the United States.

What we do not do

We do not give dosing for personal use, recommend the compound, or imply it is safe or effective for any individual. We do not name any commercial brand of the peptide. We do not host a person, address, phone number, or clinical team — there are none to host. We summarize what the literature found, cite it, and leave clinical decisions where they belong: with qualified clinicians and the primary evidence on the references page.